H.C. Wainwright analyst Swayampakula Ramakanth assumed coverage of Citius Pharmaceuticals with a Buy rating and $4 price target. The company's lead asset, Lymphir, is approved for the treatment of relapsed or refractory stage I-III cutaneous T-cell lymphoma, the analyst tells investors in a research note. The firm believes the early launch metrics are encouraging, including nearly 100% commercial lives covered, 83% of target accounts on formulary or in active review, and an initial European shipment via an international distribution partner.
